Journal ArticleDOI
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
Reads0
Chats0
TLDR
Recently, the FLAURA trial showed significantly improved progression-free survival with osimertinib compared with the first generation EGFR tyrosine kinase inhibitors gefitinib or erlotinib; this has led to its approval by US FDA and European Medicines Agency as frontline therapy.Abstract:
Mutations in the EGFR occur in approximately 10-35% of non-small-cell lung cancer (NSCLC) patients. Osimertinib is a third-generation oral small molecule inhibitor of EGFR, active against the common targetable activating EGFR mutations in L858R and exon 19 deletion; it also inhibits the T790M mutation. It was initially developed and approved for the treatment of acquired resistance to EGFR inhibition mediated by the T790M pathway activation. Recently, the FLAURA trial showed significantly improved progression-free survival with osimertinib compared with the first generation EGFR tyrosine kinase inhibitors gefitinib or erlotinib; this has led to its approval by US FDA and European Medicines Agency (EMA) as frontline therapy. Ongoing studies will define the resistance mechanisms to osimertinib, novel combination approaches and role in earlier stages of NSCLC.read more
Citations
More filters
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Journal ArticleDOI
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Adileh Ayati,Setareh Moghimi,Somayeh Salarinejad,Maliheh Safavi,Behjat Pouramiri,Alireza Foroumadi +5 more
TL;DR: The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.
Journal ArticleDOI
An update on the immune landscape in lung and head and neck cancers
TL;DR: An overview of the current immune landscape and future directions in lung cancer and HNSCC is provided to provide a plausible biological rationale to expect that pharmacologic activation of the immune system will be effective for early‐stage and smaller tumors.
Journal ArticleDOI
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
Alessandro Gambella,Rebecca Senetta,Giammarco Collemi,Stefano Vallero,Matteo Monticelli,Fabio Cofano,Pietro Zeppa,Diego Garbossa,Alessia Pellerino,Roberta Rudà,Riccardo Soffietti,Franca Fagioli,Mauro Papotti,Paola Cassoni,Luca Bertero +14 more
TL;DR: It is expected that detection of NTRK fusions will soon become a mainstay in the diagnostic assessment of CNS tumors, and thus in-depth knowledge regarding this topic is warranted.
Journal ArticleDOI
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
TL;DR: Erlotinib plus bevacizumab or ramucirumab in EFGR-mutated NSCLC first-line setting yielded remarkable PFS benefits; however, this was accompanied by higher AEs, and epidermal growth factor receptor–TKI plus antiangiogenic agent therapy may be considered a new option for advanced EGFR-mutations patients.
References
More filters
Journal ArticleDOI
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK.
TL;DR: Recent evidence that Bim proteins are regulated by phosphorylation is considered and the kinases responsible, the phosphorylations sites and effect of phosphorylated proteins on Bim protein function are discussed, seeking to resolve some of the contradictions.
Journal ArticleDOI
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Dalia Ercan,Hwan Geun Choi,Cai-Hong Yun,Marzia Capelletti,Ting Xie,Michael J. Eck,Nathanael S. Gray,Pasi A. Jänne +7 more
TL;DR: The findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clinical EG FR inhibitors that will guide the development of new strategies to inhibit EGFR.
Journal ArticleDOI
Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
Bart Lutterbach,Qinwen Zeng,Lenora Davis,Harold Hatch,Gaozhen Hang,Nancy E. Kohl,Jackson B. Gibbs,Bo-Sheng Pan +7 more
TL;DR: The results strongly suggest that Met amplification identifies a subset of NSCLC likely to respond to new molecular therapies targeting Met, which is implicated in growth, invasion, and metastasis of many tumors includingNSCLC.
Journal ArticleDOI
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol.
TL;DR: A multiple pathway model is presented, which demonstrates that MCL1 can undergo distinct phosphorylation events – mediated through separate signaling processes and involving different target sites – in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid.
Journal ArticleDOI
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson,Stephanie S. Yee,Andrea B. Troxel,Samantha L. Savitch,Ryan Fan,David Balli,David B. Lieberman,Jennifer J.D. Morrissette,Tracey L. Evans,Joshua Bauml,Charu Aggarwal,John A. Kosteva,Evan W. Alley,Christine Ciunci,Roger B. Cohen,Stephen J Bagley,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Corey J. Langer,Anil Vachani,Erica L. Carpenter +21 more
TL;DR: Therapeutically targetable driver and resistance mutations can be detected by ctDNA NGS, even when tissue is unavailable, thus allowing more accurate diagnosis, improved patient management, and serial sampling to monitor disease progression and clonal evolution.
Related Papers (5)
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience:
Ivana Sullivan,David Planchard +1 more